Meet ApplyKite Twin, the application assistant that learns with you

Meet your Twin, it learns with you

Your Twin learns with you

Launch week codes:30% off annual Pro20% off monthly Pro

Ends in00h00m00s

Constantine S. Tam

Has grant

Australia

Research Interests

Explore related searches

Professors in Australia Professors in Immunology Immunology professors in Australia

Recent Grants

Grant: Close

TACI: A Novel Immune Checkpoint in CLL

Open Date: 2018-01-01

Close Date: 2021-01-01

Grant: Close

Centre of Research Excellence in CLL at the Victorian Comprehensive Cancer Centre

Open Date: 2017-01-01

Close Date: 2019-01-01

Grant: Close

Benefit of 2D-Strain Surveillance in Improving Cardiovascular Outcomes in Cancer Patients Undergoing Cardiotoxic Chemotherapy

Open Date: 2017-01-01

Close Date: 2021-01-01

Grant: Close

Circulating Tumour DNA to Monitor Treatment Response and Resistance in Chronic Lymphocytic Leukaemia

Open Date: 2016-01-01

Close Date: 2018-01-01

Grant: Close

Australasian, Phase II, Multicentre, Randomised Study of Efficacy and Safety for Dose Reduced Fludarabine, Cyclophosphamide and Intravenous Obinutuzumab versus Oral Chlorambucil and i.v. Obinutuzumab in Previously Untreated, Comorbid, Elderly (≥65 years) Patients with CLL

Open Date: 2015-01-01

Close Date: 2017-01-01

Articles (26)

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Collaborators (17)

Samantha Jaglowski

Professor

Medical College of Wisconsin

UNITED STATES

Constantine S. Tam

Research Interests

Explore related searches

Recent Grants

Articles (26)

Five-Year Analysis of the JULIET Trial of Tisagenlecleucel in Patients With Relapsed/Refractory Large B-Cell Lymphoma

Diagnosis and Management of Chronic Lymphocytic Leukemia with TP53 Loss of Function in the Novel Agent Era

Association between patient-reported symptoms and clinical outcomes in R/R CLL

Indirect Comparison of the Efficacy of Zanubrutinib vs Ibrutinib and Acalabrutinib in Treatment-Naive Chronic Lymphocytic Leukemia: 6-Year Follow-Up

Richter transformation: emerging immunologic strategies beyond chemoimmunotherapy

Estimated cardiac deaths associated with treating chronic lymphocytic leukemia with ibrutinib versus zanubrutinib in the United States

Marginal zone lymphoma is associated with dysregulated T-cell immunity that is not altered by ibrutinib-venetoclax treatment

Zanubrutinib for the treatment of patients with del(17p) and/or TP53 CLL/SLL: analysis across clinical studies

Number needed to treat to avoid progression and death and cost analysis: zanubrutinib versus acalabrutinib in relapsed/refractory chronic lymphocytic leukemia

First-line treatment for CLL in the era of targeted therapy

Australia and New Zealand consensus statement on the cardiovascular management of patients with chronic lymphocytic leukaemia treated with Bruton's tyrosine kinase inhibitors

Enhanced Disease Detection of Hairy Cell Leukaemia Through Next‐Generation Sequencing Based BRAFV600E and Phased Variant Analysis

Acquired mutations in patients with relapsed/refractory CLL who progressed in the ALPINE study

Novel mechanisms of resistance in CLL: variant BTK mutations in second-generation and noncovalent BTK inhibitors

Clinically appropriate dose reductions and interruptions do not compromise efficacy in patients receiving treatment with ibrutinib

Allogeneic stem cell transplantation achieves long-term remissions in mantle cell lymphoma, including in TP53-mutated disease

Zanubrutinib Versus Ibrutinib in Relapsed/Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma: Interim Analysis of a Randomized Phase III Trial

Outcomes in Patients with High-Risk Features after Fixed-Duration Ibrutinib plus Venetoclax: Phase II CAPTIVATE Study in First-Line Chronic Lymphocytic Leukemia

Zanubrutinib Versus Ibrutinib in Symptomatic Waldenström Macroglobulinemia: Final Analysis From the Randomized Phase III ASPEN Study

Immune restoration with ibrutinib plus venetoclax in first-line chronic lymphocytic leukemia: the phase 2 CAPTIVATE study

Zanubrutinib: past, present, and future

Real-world experience of combined treatment with azacitidine and romidepsin in patients with peripheral T-cell lymphoma

Zanubrutinib for the treatment of relapsed/refractory hairy cell leukemia

Ocular toxoplasmosis during frontline venetoclax therapy for chronic lymphocytic leukaemia – more than meets the eye

Report of consensus panel 7 from the 11th international workshop on Waldenström macroglobulinemia on priorities for novel clinical trials

Long-term safety for patients with tisagenlecleucel-treated relapsed/refractory diffuse large B-cell lymphoma

Collaborators (17)

Samantha Jaglowski

Martin Šimkovič

Edmund K. Waller

Peter Hillmen

David Ritchie

Stephan Mielke

Harald Holte

Amit Khot

Thomas Kipps

Stephen Opat

Ulrich Jaeger

Paolo Ghia

Paul M. Barr

Philip A Thompson

Charalambos Andreadis

Josephine M.I. Vos

Tanya Siddiqi

Make your next move.